ArticleCritical care (London, England)2017
Monocyte programmed death ligand-1 expression is an early marker for predicting infectious complications in acute pancreatitis.
Article in Critical care (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 40 citations in OpenAlex.
- Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial.Intensive care medicine · 2022Trial
- Anti-PD-L1 therapy to prevent systemic immune suppression after polytraumatic brain injury in rats.The journal of trauma and acute care surgery · 2026Article
- Pancreatitis Unveiled: Linking Pathogenesis, Organ Failure, and Emerging Predictive Biomarkers.Cureus · 2025Review
- Early prediction and prevention of infected pancreatic necrosis.World journal of gastroenterology · 2024Article
- PD-L1 Blockade Improves Survival in Sepsis by Reversing Monocyte Dysfunction and Immune Disorder.Inflammation · 2024Article
- Early dynamic changes to monocytes following major surgery are associated with subsequent infections.Frontiers in immunology · 2024Observational
- Association between pretreatment lymphocyte count and efficacy of immune-enhancing therapy in acute necrotising pancreatitis: a post-hoc analysis of the multicentre, randomised, placebo-controlled TRACE trial.EClinicalMedicine · 2023Article
- Programmed cell death ligand 1 expression on monocytes is inversely correlated with tumour response to preoperative chemoradiotherapy for locally advanced rectal cancer.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2022Article
- The Expression Levels and Concentrations of PD-1 and PD-L1 Proteins in Septic Patients: A Systematic Review.Diagnostics (Basel, Switzerland) · 2022Review
- Intermediate Monocytes with PD-L1 and CD62L Expression as a Possible Player in Active SARS-CoV-2 Infection.Viruses · 2022Article
- Upregulation of PD-1 Expression and High sPD-L1 Levels Associated with COVID-19 Severity.Journal of immunology research · 2022Article
- Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Review
- Fire in the belly: A scoping review of the immunopathological mechanisms of acute pancreatitis.Frontiers in immunology · 2022Article
- Immunomonitoring of Monocyte and Neutrophil Function in Critically Ill Patients: From Sepsis and/or Trauma to COVID-19.Journal of clinical medicine · 2021Review
- Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases.Cancers · 2021Review
- Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients.Clinical and translational medicine · 2021Article
- Serum soluble PD-1 plays a role in predicting infection complications in patients with acute pancreatitis.Immunity, inflammation and disease · 2021Article
- Soluble B7-H5 Is a Novel Diagnostic, Severity, and Prognosis Marker in Acute Pancreatitis.BioMed research international · 2021Article
- Increased percentage of PD-L1Critical care (London, England) · 2020Observational
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute pancreatitis (AP) is a life-threatening disease that requires early identification of patients at risk of developing infectious complications. Immunosuppression is an initial event that is key to AP pathogenesis. The programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) system is reported to mediate evasion of host immune surveillance in many diseases; however, the relationship between PD-1/PD-L1 expression and these parameters or infectious complications in AP has not been elucidated. This study was conducted to determine whether PD-1 and PD-L1 are upregulated and to reveal the relationship between PD-1/PD-L1 expression and the development of infectious complications in AP.
methodsSixty-three patients with AP and 32 sex- and age-matched healthy control subjects were prospectively enrolled. On days 1 and 3 after the onset of AP, we measured PD-1 expression in peripheral CD4
resultsCompared with healthy volunteers, the percentages of PD-1-expressing CD4
conclusionsThe PD-1/PD-L1 system plays an essential role in the early immunosuppression of AP. PD-L1 expression in CD14
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.